Discover
HCWB
HCW Biologics Inc.
4.58
2 x 3.47
2 x 5.61
bid
ask
-
0.41
8.22%
2 @ 04:00 AM
4.56 -0.02 (0.52%)
| Ytd | 371.68% | |
| 1y | 22.13% |
4.39
day range
4.98
1.50
52 week range
44.10
| Open | 4.86 | Prev Close | 4.99 | Low | 4.39 | High | 4.98 | Mkt Cap | 7.31M |
| Vol | 72.39K | Avg Vol | 2.15M | EPS | -49.74 | P/E | N/A | Forward P/E | -0.73 |
| Beta | 0.84 | Short Ratio | 0.28 | Inst. Own | 3.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.58 | 200-d Avg | 10.30 | 1yr Est | 3.00 |
HCWB News
benzinga.com
HCW Biologics Regains Nasdaq Compliance After Announcing 1-For-6 Reverse Stock Split, Effective June
HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a U.S.-based c
globenewswire.com
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics
benzinga.com
HCW Biologics Announces 1-For-6 Reverse Stock Split, Effective June 30
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based cl
globenewswire.com
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock s
benzinga.com
Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss
HCW Biologics reports positive Phase 1 data for HCW9302, with all 2nd-cohort alopecia patients showi
benzinga.com
HCW Biologics Says Preliminary Human Data For The First Two Dose Cohorts From Its Dose-escalating Ph
Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating r
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
HCW Biologics Files Prospectus For Offering 5.69M Common Shares
https://www.sec.gov/Archives/edgar/data/1828673/000149315226027656/forms-1.htm